Clinical trials: Steatosis
Overweight and Obesity, Type2 Diabetes
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by…
- Conditions
- Overweight and Obesity, Type2 Diabetes, NAFLD
- Trial name
- NCT04812262
- Testing
- DD01
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 255 people
- Sponsor
- Neuraly, Inc.
Non Alcoholic Fatty Liver Disease
Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease
This study was conducted on patients presenting to Mayo Hospital, Lahore from 24th August, 2023 till 23rd May, 2024. Ninety patients conforming to the inclusion criteria were selected via simple random sampling technique and…
- Trial name
- NCT07104786
- Testing
- Obeticholic Acid 10 MG, Vitamin E 400mg
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- King Edward Medical University
Non Alcoholic Fatty Liver Disease
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
The purpose of the study is to evaluate the efficacy and safety of Niacinamide supplementation on clinical outcome of fatty liver patients having type II DM through measurement of the following before and after Niacinamide…
- Trial name
- NCT03850886
- Testing
- Niacinamide Oral Tablet, Antidiabetic
- Where
- Egypt
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Nonalcoholic Steatohepatitis, Insulin Resistance
Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether the addition of Diamel, a nutritional supplement, to hypocaloric diet and exercise could improve the histological results (steatosis, necro-inflammatory activity and fibrosis)…
- Trial name
- NCT00820651
- Testing
- Diamel
- Where
- Cuba
- Volunteers
- 158 people
- Sponsor
- Catalysis SL
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Post-cholecystectomy Metabolic Changes -Hepatic Steatosis
Fatty Liver in Long Standing Cholecystectomy
This observational study aims to evaluate the association between long-term cholecystectomy and the development of metabolic dysfunction-associated fatty liver disease (MAFLD) in adult patients.
- Trial name
- MAFLD-Chole St (NCT07284004)
- Volunteers
- 100 people
- Sponsor
- Yasmeen Ahmed Farrag Ahmed
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01712711
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Nonalcoholic Steatohepatitis (NASH)
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT04616014
- Testing
- ORMD-0801 QD
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Oramed, Ltd.
Chronic Hepatitis b, Non-Alcoholic Fatty Liver Disease
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled.
- Trial name
- NCT05786963
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Pancreatic Exocrine Insufficiency
Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients
to investigate the frequency of PEI in MAFLD
- Trial name
- NCT05804409
- Testing
- FECAL ELASTASE
- Volunteers
- 70 people
- Sponsor
- Assiut University
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00699036
- Testing
- avandia, metformin, losartan
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Brooke Army Medical Center
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
Chronic Hepatitis C Virus, Non Alcoholic Fatty Liver Disease
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
Chronic hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD) are characterized by a spectrum of pathological conditions ranging from an early stage of inflammation and fibrosis up to more advanced…
- Trial name
- NCT02038387
- Testing
- normocaloric low cholesterol diet
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Roma La Sapienza
Fatty Liver
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.
- Trial name
- NAFLD (NCT00736385)
- Testing
- Glucophage (Metformin)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.
- Trial name
- NCT06218342
- Testing
- Henagliflozin, Background medication
- Volunteers
- 156 people
- Sponsor
- Sir Run Run Shaw Hospital
Metabolic Associated Fatty Liver Disease, Clinical Features
Clinical Characteristics of Metabolic Associated Fatty Liver Disease
Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society.
- Trial name
- NCT06325254
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nonalcoholic Steatohepatitis
Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis
This study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of Rosuvastatin versus Coenzyme Q10 on nonalcoholic steatohepatitis patients.
- Trial name
- NCT05731596
- Testing
- Rosuvastatin 20 Mg Oral Tablet, Coenzyme Q10 100 MG Oral Capsule
- Volunteers
- 46 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
Longitudinal Observational Study Of Chinese With NAFLD/NASH
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Trial name
- NCT03151473
- Where
- Hong Kong
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Humanity and Health Research Centre
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-alcoholic Fatty-liver Disease
Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis
Primary Objectives: 1. To determine whether a 4 week reduction in dietary fructose intake improves hepatic steatosis in overweight children who have a baseline high fructose consumption and hepatic steatosis. 2.
- Trial name
- Sweet Bev (NCT01188083)
- Testing
- Fructose Drink, Glucose Drink
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.